{"filing":{"accession_number":"0001034842-26-000053","cik":"0001034842","ticker":"RIGL","company_name":"RIGEL PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"rigl-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000053/rigl-20260804.htm"},"events":[{"id":23807,"run_id":21533,"accession_number":"0001034842-26-000053","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Rigel disclosed second quarter 2026 financial results via a press release furnished as Exhibit 99.1 under Item 2.02. The disclosure includes total revenues of $78.7 million, net income of $17.3 million, and updated 2026 guidance of $285–$295 million in total revenues. This is a standard quarterly earnings release that would materially affect a reasonable investor's assessment of the company's financial performance and outlook.","company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24143,"accession_number":"0001034842-26-000053","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Rigel disclosed second quarter 2026 financial results via a press release furnished as Exhibit 99.1 under Item 2.02. The disclosure includes total revenues of $78.7 million, net income of $17.3 million, and updated 2026 guidance of $285–$295 million in total revenues. This is a standard quarterly earnings release that would materially affect a reasonable investor's assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:18:47.999069+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24143,"accession_number":"0001034842-26-000053","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Rigel disclosed second quarter 2026 financial results via a press release furnished as Exhibit 99.1 under Item 2.02. The disclosure includes total revenues of $78.7 million, net income of $17.3 million, and updated 2026 guidance of $285–$295 million in total revenues. This is a standard quarterly earnings release that would materially affect a reasonable investor's assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:18:47.999069+00:00","company_name":"RIGEL PHARMACEUTICALS INC","ticker":"RIGL","filing_date":"2026-08-04"}]}